Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $28.00

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has earned an average recommendation of "Hold" from the six analysts that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $28.00.

SNN has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group lowered shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Finally, HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently added to or reduced their stakes in the stock. River Road Asset Management LLC grew its holdings in Smith & Nephew SNATS by 64.0% in the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock worth $49,947,000 after buying an additional 792,829 shares in the last quarter. J. Goldman & Co LP acquired a new position in Smith & Nephew SNATS during the 4th quarter worth $47,700,000. Goldman Sachs Group Inc. boosted its position in Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock worth $50,255,000 after acquiring an additional 583,809 shares during the period. Armistice Capital LLC grew its stake in shares of Smith & Nephew SNATS by 258.1% in the first quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider's stock worth $50,187,000 after purchasing an additional 1,275,000 shares in the last quarter. Finally, Brandes Investment Partners LP increased its holdings in shares of Smith & Nephew SNATS by 11.4% during the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock valued at $33,504,000 after purchasing an additional 138,994 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Stock Performance

Shares of SNN traded up $0.66 during mid-day trading on Wednesday, hitting $31.35. The stock had a trading volume of 1,051,030 shares, compared to its average volume of 817,559. Smith & Nephew SNATS has a fifty-two week low of $23.69 and a fifty-two week high of $31.72. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The company has a market cap of $13.73 billion, a PE ratio of 14.52, a PEG ratio of 0.92 and a beta of 0.69. The company's fifty day simple moving average is $29.24 and its two-hundred day simple moving average is $27.37.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.